 Gossamer Bio NASDAQ:GOSS was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, ... 